Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$198.86 USD

198.86
4,683,324

+2.56 (1.30%)

Updated Aug 7, 2025 04:00 PM ET

Pre-Market: $199.45 +0.59 (0.30%) 8:30 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (85 out of 244)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

Zacks Equity Research

AbbVie (ABBV) to Acquire ImmunoGen (IMGN) for $10.1 Billion

by Zacks Equity Research

AbbVie (ABBV) offers to buy ImmunoGen (IMGN) for approximately $10.1 billion, which will diversify its oncology pipeline across solid tumors and hematologic malignancies.

Derek Lewis headshot

This Combination of 3 Stocks Provides Monthly Income

by Derek Lewis

Investors who select stocks in a structured manner can create a portfolio that pays them monthly. Who doesn't love payday?

Zacks Equity Research

AbbVie (ABBV) Posts Encouraging Data From Lung Cancer Study

by Zacks Equity Research

Data from a mid-stage study on AbbVie's (ABBV) experimental ADC drug demonstrates compelling clinical benefits across key endpoints in certain lung cancer patients.

Zacks Equity Research

Is it a Good Idea to Invest in Harpoon (HARP) Stock Now?

by Zacks Equity Research

Here, we discuss some reasons why investing in Harpoon Therapeutics (HARP) stock now may turn out to be a prudent move.

Zacks Equity Research

The Zacks Analyst Blog Highlights AbbVie, J&J, Eli Lilly, Pfizer

by Zacks Equity Research

AbbVie, J&J, Eli Lilly, Pfizer are included in this Analyst Blog.

Kinjel Shah headshot

4 Large Drug Stocks to Watch as IBD Market Gains Traction

by Kinjel Shah

As demand for novel IBD treatments rises, investment in this dynamic sector could be rewarding. Some of the key players in the market are AbbVie (ABBV), J&J (JNJ), Lilly (LLY) and Pfizer (PFE).

Zacks Equity Research

AbbVie (ABBV) Lymphoma Drug Gets FDA Breakthrough Therapy Tag

by Zacks Equity Research

The FDA grants breakthrough therapy designation to AbbVie's (ABBV) Epkinly in follicular lymphoma indication. The EMA validates a regulatory filing seeking label expansion for the drug.

Zacks Equity Research

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

by Zacks Equity Research

Sector ETF report for PJP

Zacks Equity Research

AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

Zacks Equity Research

Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for DHS

Zacks Equity Research

J&J (JNJ) Seeks Expanded Use of Lung Cancer Drug Rybrevant

by Zacks Equity Research

J&J's (JNJ) sBLA seeks label expansion for Rybrevant plus chemotherapy to treat patients with EGFR-mutated NSCLC whose disease progressed on or after treatment with AstraZeneca's Tagrisso (osimertinib).

Zacks Equity Research

ABBV vs. LLY: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

ABBV vs. LLY: Which Stock Is the Better Value Option?

Zacks Equity Research

Should You Invest in AbbVie (ABBV) Based on Bullish Wall Street Views?

by Zacks Equity Research

The average brokerage recommendation (ABR) for AbbVie (ABBV) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Zacks Equity Research

Should SPDR S&P Dividend ETF (SDY) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SDY

Zacks Equity Research

Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, J&J and AbbVie

by Zacks Equity Research

Eli Lilly, Novo Nordisk, J&J and AbbVie are part of the Zacks Industry Outlook article.

Kinjel Shah headshot

4 Large Drug Stocks Likely to Sail Through Industry Woes

by Kinjel Shah

Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), J&J (JNJ) and AbbVie (ABBV) are worth retaining in your portfolio.

Zacks Equity Research

Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know

by Zacks Equity Research

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Equity Research

The Zacks Analyst Blog Highlights NVIDIA, Chevron, AbbVie, Alibaba Group Holding and Morgan Stanley

by Zacks Equity Research

NVIDIA, Chevron, AbbVie, Alibaba Group Holding and Morgan Stanley are part of the Zacks top Analyst Blog.

Sheraz Mian headshot

Top Research Reports for NVIDIA, Chevron & AbbVie

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Chevron Corporation (CVX) and AbbVie Inc. (ABBV).

Zacks Equity Research

Ironwood's (IRWD) Q3 Earnings Miss Mark, Linzess Volume Rises

by Zacks Equity Research

Ironwood's (IRWD) third-quarter 2023 earnings miss estimates, while revenues beat the same. Linzess collaboration revenues drive the top line.

Zacks Equity Research

Is SPDR S&P Dividend ETF (SDY) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for SDY

Zacks Equity Research

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Zacks Equity Research

The Zacks Analyst Blog Highlights AbbVie, Exxon Mobil, Kontoor Brands, Select Water Solutions and Macatawa Bank

by Zacks Equity Research

AbbVie, Exxon Mobil, Kontoor Brands, Select Water Solutions and Macatawa Bank are part of the Zacks top Analyst Blog.

Zacks Equity Research

Amgen (AMGN) Beats on Q3 Earnings Beat, Lags Sales, Ups View

by Zacks Equity Research

Amgen (AMGN) beats Q3 estimates for earnings but misses on sales. Following the acquisition of Horizon Therapeutics, it raises earnings and sales guidance for 2023.

Zacks Equity Research

Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock

by Zacks Equity Research

AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.